Pamela Vig, Ph.D. is a co-founder of Mirum and serves as chief scientific officer and head of research. She is responsible for medical and scientific affairs, non-clinical and research initiatives.

Pam has more than 30 years of industry experience in clinical development, medical affairs and translational science in various liver diseases including hepatitis B (HBV), hepatitis C (HCV), nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and cholestatic liver disease, as well as HIV and other infectious diseases. Before joining Mirum, Pam held leadership roles at Allergan plc and Tobira Therapeutics as vice president of clinical research and discovery, as well as vice president of clinical research at Presidio Pharmaceuticals, Inc. Pam previously served as director, global medical affairs, at Johnson & Johnson in London, UK, and also held positions in clinical research and development at Idenix Pharmaceuticals and Gilead Sciences, Inc. Pam is the industry co-chair for the PSC Forum Steering Committee as well as co-chair for the Pediatric Cholestatic Disease working Group under the Forum for Collaborative Research.

Pam holds a Ph.D. from Imperial College London in the departments of hepatology and histopathology.

From September 2015 to December 2017, Ms. Brege served as managing director of Cervantes Life Science Partners, LLC, a consulting firm providing integrated business solutions to life sciences companies. She has over 20 years of executive management experience in the pharmaceutical, biotechnology, and venture capital industries. From September 2012 to July 2015, Ms. Brege was president and chief executive officer of Nodality, Inc., a life sciences company focused on innovative personalized medicine. Prior to joining Nodality in 2012, Ms. Brege held several senior-level positions at Onyx Pharmaceuticals, Inc., a biopharmaceutical and biotherapeutics company, from 2006 to 2012, including positions as executive vice president and chief operating officer. While at Onyx, she led multiple functions, including commercialization, strategic planning, corporate development, and medical, scientific, and government affairs. Prior to Onyx, Ms. Brege was a General Partner at Red Rock Capital Management, a venture capital firm specializing in early stage financing for technology companies. Previously, Ms. Brege was senior vice president and chief financial officer at COR Therapeutics Inc. where she helped build the company from an early-stage research and development company through commercial launch of a successful cardiovascular product. Earlier in her career, she served as chief financial officer at Flextronics, Inc., and Treasurer of The Cooper Companies. She serves on the boards of directors of Acadia Pharmaceuticals Inc., Dynavax Technologies Corporation, Pacira BioSciences, Inc., Portola Pharmaceuticals, Inc., and HLS Therapeutics Inc., each of which is a public pharmaceutical company. During the past 5 years, Ms. Brege also served on the boards of directors of Delcath Systems, Inc., a pharmaceutical company, and Aratana Therapeutics, Inc., a pharmaceutical company. Ms. Brege earned her undergraduate degrees from Ohio University (Honors Tutorial College) and her M.B.A. degree from the University of Chicago.

Patrick Heron has served as a member of our board of directors since November 2018. Mr. Heron is a general partner with Frazier, a position he has held since September 1999. Mr. Heron has been active in company formations and initial investments in various biotechnology companies, including Marcadia Biotech Inc., Calixa Therapeutics, Inc., and VentiRx Pharmaceuticals, Inc., He also led Frazier’s involvement in MedPointe Inc. Prior to joining Frazier, Mr. Heron helped develop McKinsey & Co.’s West Coast biotechnology consulting practice. Mr. Heron currently serves on the board of directors of Iterum Therapeutics pic, a public pharmaceutical company, as well as private companies Amunix Therapeutics, Inc., Imago Biosciences, Inc., Silvergate Pharmaceuticals, Inc., Arcutix, Inc., SutroVax, Inc., PassageBio, Inc., and Recida Therapeutics, Inc. He previously served on the boards of directors of the public biopharmaceutical companies Tobira and Collegium Pharmaceuticals, Inc. Mr. Heron received a B.A. in political science from the University of North Carolina at Chapel Hill and an M.B.A. from Harvard Business School.

Tim Walbert is currently senior advisor, Amgen. Most recently, Mr. Walbert served as the chairman, president and chief executive officer of Horizon Therapeutics from 2008 to October 2023, when it was acquired by Amgen for $28.3 billion. Before joining Horizon, he was president, chief executive officer and director of IDM Pharma Inc., a public biotechnology company, which was acquired by Takeda America Holdings Inc., or Takeda, in June 2009. Before IDM, Mr. Walbert served as executive vice president, commercial operations at NeoPharm Inc., a public biotechnology company. From 2001 to 2005, he was divisional vice president and general manager, immunology, at Abbott, now AbbVie, leading the global development and launch of the multi-indication biologic HUMIRA, and served as divisional vice president, global cardiovascular strategy. From 1998 to 2001, Mr. Walbert served as director, CELEBREX North America, and arthritis team leader, Asia Pacific, Latin America and Canada, at G.D. Searle & Company. From 1991 to 1998, he also held sales and marketing roles with increasing responsibility at G.D. Searle, Merck & Co. Inc. and Wyeth.

He serves on the boards of Century Therapeutics and Sagimet Biosciences, both public biotech companies, Cour Pharmaceuticals, Odyssey Therapeutics and Latigo Therapeutics (chairman), each private clinical-stage biotech companies. He is also a member of the Board of Trustees of Muhlenberg College. He previously served on the board of directors for Aurinia Pharmaceuticals, a public pharmaceutical company, from 2020 to 2022, Exicure, a public biotechnology company, from 2019 to 2022, Assertio, a public biopharma company, from 2014 to 2020, Raptor Pharmaceutical Corp., a public biotechnology company, from 2010 to 2014; XOMA Corporation, a public biotechnology company, from 2011 to 2017 and Sucampo Pharmaceuticals Inc., a public biopharmaceutical company, from 2016 to 2018. He is also a member of Economic Club of Chicago, the Commercial Club of Chicago and the Civic Committee of the Commercial Club of Chicago. Mr. Walbert was a previous board member of the Biotechnology Innovation Organization (BIO), the Pharmaceutical Research and Manufacturing Association (PhRMA), the Illinois Biotechnology Innovation Organization (iBIO) and World Business Chicago. Mr. Walbert received a Bachelor of Arts in business from Muhlenberg College in Allentown, PA.

Lon Cardon, Ph.D., FMedSci, an internationally recognized human geneticist, joined The Jackson Laboratory as president and chief executive officer in November 2021.  From 2017 to 2021, he was chief scientific officer and chief scientific strategy officer at BioMarin Pharmaceutical Inc., a rare disease biotechnology company, where he led a strategic repositioning from ultra-rare genetic diseases to broader genetic disorders. Before joining BioMarin, Cardon held leadership roles at GlaxoSmithKline.

Cardon spent the first half of his career in academic research, holding senior roles at the University of Oxford and the Wellcome Trust Centre for Human Genetics (1998- 2006) and at the University of Washington and the Fred Hutchinson Cancer Research Center (2006-2008).

Cardon conducted his Ph.D. research at the Institute for Behavior Genetics at the University of Colorado Boulder and completed postdoctoral training in mathematics at Stanford University.  His research groups have been involved in large international genetics initiatives that helped to create the present global genomics research infrastructure, including the first Genome-Wide Association Studies; the discovery of numerous genes responsible for rare diseases; and the development of new treatments for genetic disorders.

Carol L. Brosgart, M.D., has served as a member of our board of directors since June 2021. Dr. Brosgart has extensive clinical, public policy, advocacy, and corporate experience having held senior management, board, and advisory positions in a number of settings. In addition to various advisory roles, Dr. Brosgart serves as an independent director on the boards of both public and privately held biotechnology companies (Galmed, Abivax, Enochian, and Intrivo Diagnostics) and previously served on the boards of Tobira and Juvaris, until their acquisitions. Dr. Brosgart’s senior management experience in biotechnology and healthcare included chief medical officer roles at Alios BioPharma and UCSF Benioff Children’s Hospital and Research Center and vice president, public health and policy at Gilead where she was responsible for the clinical development and approval of 2 antiviral therapies: Viread® for the treatment of HIV and Hepsera® for the treatment of chronic hepatitis B. Prior to Gilead, Dr. Brosgart worked for more than 20 years in public health, including clinical care, research, and teaching. Dr. Brosgart also is active in public policy through advocacy and advisory and board roles for numerous organizations and foundations, including the American Liver Foundation, the Hepatitis B Foundation, the SF AIDS Foundation, and Forum for Collaborative Research.

Trained as a pediatrician and in public health and preventive medicine, she was among the first physicians in the United States to recognize and treat patients with HIV/AIDS. Dr. Brosgart was the founding Medical Director of the East Bay AIDS Center at Alta Bates Medical Center in Berkeley, California. She led NIH clinical trials as a member of the Community Programs for Clinical Research on AIDS (CPCRA), chaired the CPCRA Scientific Advisory Committee, and contributed to HIV antiretroviral drug development and to the development of prophylactic and treatment agents for opportunistic and malignant complications of HIV/AIDS. Dr. Brosgart also served as senior advisor on science and policy to the Division of Viral Hepatitis at the Centers for Disease Control from 2011 to 2014.

William C. Fairey has served on Mirum’s board of directors since 2021. Mr. Fairey brings nearly 30 years of experience building strong and scalable global commercial organizations. Most recently, Mr. Fairey served as executive vice president and chief commercial officer at MyoKardia where he built the commercial and portfolio strategy, established the company’s European headquarters, and was structuring the expansion in Latin America and Asia when the company was acquired by Bristol-Myers Squibb. Mr. Fairey held a similar role at ChemoCentryx, where, as chief operations officer, he was responsible for building out the initial commercial and medical teams. Prior to ChemoCentryx, he served in a number of roles at Actelion Pharmaceuticals, including president of the U.S. division. Before taking that role, Mr. Fairey developed Actelion’s Asia-Pacific business, creating new opportunities in China, Taiwan, and Southeast Asia, and chaired the board of directors for Actelion China. He was also president of Actelion Canada and vice president, sales and managed markets, one of the founding members of the U.S. executive team.

Mr. Fairey received his undergraduate degree from the University of Oregon and an M.B.A. from Saint Mary’s College.

Niall O’Donnell, Ph.D., has served as a member of our board of directors since November 2018. Dr. O’Donnell is currently a managing director at RiverVest Venture Partners, a position he has held since April 2014. He joined RiverVest in 2006 where he has focused on biopharmaceutical, diagnostic, and medical device opportunities and contributes to the formation, development, and business strategies of RiverVest portfolio companies. Dr. O’Donnell currently serves as president and chief executive officer of Reneo, which he co-founded in December 2017. From 2011 to 2013, he served as acting chief interim medical officer at Lumena, where he led the development and execution of the company’s clinical strategy leading up to its acquisition by Shire plc. Dr. O’Donnell is also a board member of the biopharmaceutical companies Amplyx, Lyric Pharmaceuticals Inc., Avalyn Pharma, Inc., Curzion, and Spruce Biosciences. Dr. O’Donnell received a Ph.D. in biochemistry from the University of Dundee, Scotland, an M.A. in biochemistry from Pembroke College, Oxford, and an M.B.A. from the Rady School of Management of the University of California, San Diego.

Laurent Fischer, M.D., is Adverum’s president and chief executive officer and serves as a director. Dr. Fischer has more than 20 years of drug development and commercialization experience in the biopharmaceutical industry. Before joining Adverum, Dr. Fischer was senior vice president and head of the Liver Therapeutic Area at Allergan, PLC. Previously, he served as chairman and chief executive officer of Tobira Therapeutics until its acquisition by Allergan in November 2016. He also served as chairman and chief executive officer of Jennerex, Inc. until its acquisition by SillaJen Biotherapeutics, Inc. Prior to Jennerex, he was co-founder, president and chief executive officer of Ocera Therapeutics and president and chief executive officer of Auxeris Therapeutics, Inc. Over the span of his career, Dr. Fischer has held roles of increasing responsibility at several companies, including RXCentric, Inc. (now part of Allscripts Healthcare Solutions, Inc.), MedVantx Inc., Dupont Pharmaceuticals, Dupont-Merck, and F. Hoffmann-La Roche.

Dr. Fischer received his undergraduate degree from the University of Geneva and his medical degree from the Geneva Medical School, Switzerland.

Dr. Fischer served as chairman of the board of CTI Biopharma until its sale to SOBI in July 2017. He is a director at Atai Life, the first independent director at Nobel laureate Carolyn Bertozzi’s Lycia Therapeutics, and was a senior advisor on the Life Sciences Team at Frazier Healthcare Partners.

Chris Peetz is a co-founder of Mirum and serves as chief executive officer.

Chris has been an entrepreneur-in-residence at Frazier Healthcare Partners since May 2017. Prior to joining Mirum, Chris served as the chief executive officer of Flashlight Therapeutics, Inc. From May 2014 to December 2016, he served as chief financial officer and head of corporate development at Tobira, which was acquired by Allergan plc, in November 2016. Prior to joining Tobira, Chris served as vice president, finance and corporate development of Jennerex Biotherapeutics. Prior to Jennerex, Chris held various positions at Onyx Pharmaceuticals, Inc. (now Amgen Inc.), including corporate strategy, marketing, product lifecycle management, and financial planning. Prior to Onyx, Chris provided merger and acquisition advisory services at LaSalle Corporate Finance, a part of ABN AMRO, and held positions at Abgenix Inc. and Solazyme Inc. He also serves as a member of the board of directors of Alpine Immune Sciences, Inc., a public immunotherapy company, since April 2018.

Chris received an M.B.A. from Stanford Graduate School of Business and a B.S.B.A. in Finance, International Business and French from Washington University in St. Louis